Mark Lappe, Chief Executive Officer at Inhibrx Biosciences, Inc., bought 25,000 shares of INBX on 8 September 2026 — $2,645,399 of their own company’s stock at $105.82 a share.

That price is the entry above, and it is a real one: a Form 4 discloses the price actually paid, so this is what they paid — the average across the separate lines of the filing — rather than an estimate. It is what they paid on their own trade date, and it is not a price available now.

Other insiders at INBX bought the same day: Jon Faiz Kayyem (Director, $567,580), Douglas Forsyth (Director, $286,617). They filed at their own prices, which is what separates several people deciding from one transaction written up under several names.

Filed 8 September 2026. This post is dated when that filing reached us, because that is the first moment anyone here could have acted on it.

One person buying a lot is the whole signal here. Grants, option exercises, tax withholdings and scheduled 10b5-1 plan purchases are excluded, because none of them is somebody choosing to put money in today; so are purchases by holders who are neither officers nor directors, which are funds building a position rather than a person making a decision. An automated tracker of public SEC filings, not a recommendation.